Literature DB >> 15300456

Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.

U Frank1, M Greiner, I Engels, F D Daschner.   

Abstract

The objective of the present study was to investigate the influence of the new echinocandins caspofungin (MK-0991) and anidulafungin (LY303366) on human phagocytes. Phagocytosis, oxidative burst and intracellular killing of Candida albicans were analyzed by flow cytometry. Neither caspofungin nor anidulafungin significantly influenced phagocytosis. Only caspofungin significantly influenced oxidative burst after 15 min of incubation ( P<0.05). Both caspofungin and anidulafungin improved intracellular killing rates of C. albicans after 2 h of incubation (42.4% and 43.2%, respectively, compared to 37.9% in controls; P<0.05). In conclusion, caspofungin significantly improves oxidative burst and intracellular killing, which may be advantageous for clinical therapy. Copyright 2004 Springer-Verlag

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15300456     DOI： 10.1007/s10096-004-1171-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  10 in total

1.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

Authors:  M Del Poeta; W A Schell; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Simultaneous cytofluorometric measurement of phagocytosis, burst production and killing of human phagocytes using Candida albicans and Staphylococcus aureus as target organisms.

Authors:  H R Salih; L Husfeld; D Adam
Journal:  Clin Microbiol Infect       Date:  2000-05       Impact factor: 8.067

4.  The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus.

Authors:  T Chiller; K Farrokhshad; E Brummer; D A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  2001-02       Impact factor: 2.803

5.  Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.

Authors:  J R Graybill; R Bocanegra; M Luther; A Fothergill; M J Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

7.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Authors:  G K Abruzzo; C J Gill; A M Flattery; L Kong; C Leighton; J G Smith; V B Pikounis; K Bartizal; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus.

Authors:  T Chiller; K Farrokhshad; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 10.  Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.

Authors:  D W Denning
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790
  10 in total
  3 in total

1.  Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cells.

Authors:  Valeria Allizond; Giuliana Banche; Franca Giacchino; Chiara Merlino; Daniela Scalas; Vivian Tullio; Giuseppe Garneri; Narcisa Mandras; Janira Roana; Anna Maria Cuffini
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

2.  Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.

Authors:  Chantal Fernandes; Jorge Anjos; Louise A Walker; Branca M A Silva; Luísa Cortes; Marta Mota; Carol A Munro; Neil A R Gow; Teresa Gonçalves
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

3.  Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans.

Authors:  Vivian Tullio; Narcisa Mandras; Daniela Scalas; Valeria Allizond; Giuliana Banche; Janira Roana; Deborah Greco; Franco Castagno; Anna Maria Cuffini; Nicola A Carlone
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.